Verily builds an AI-native precision health platform that transforms multimodal health data into insights, models, and actions intended to make healthcare more personalized, predictive, and precise. The company plans to accelerate that platform strategy following a $300 million investment and a legal restructure from an LLC to Verily Health Inc. Verily has been expanding commercial relationships—announcing collaborations with Samsung’s Galaxy Watch, Salesforce, UCHealth, the University of Colorado Anschutz, and RefinedScience—for biomarker development, clinical research acceleration, and enterprise precision health solutions. Alphabet remains an investor and, after the round, holds a significant minority position rather than a controlling stake. The company positions itself at the intersection of technology, data science, and healthcare to drive AI-enabled research and care transformation.

Total raised

$3.8B

Funding rounds

5

Latest round

Equity

Latest activity

Mar 2026